Roivant Sciences
Price & Volume
Stats
See moreOpen | $10.71 |
Previous Close | $10.72 |
Day Range | $10.71-$10.85 |
52W Range | $9.76-$13.05 |
Market Cap | $7.6B |
Shares Short | 42M |
Financials
See moreRevenue (12 Mos) | $122.5M |
Revenue Growth (YoY) | -42.1% |
Gross Profit (12 Mos) | -$469.5M |
Diluted EPS | -$1 |
News
See moreYahoo Finance • 24 days ago
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025
Yahoo Finance • 5 months ago
Is Roivant Sciences Ltd. (ROIV) the Best Guru Stock To Buy Now?
Yahoo Finance • 5 months ago
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Yahoo Finance • 5 months ago
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
About
CEO | Mr. Matthew Gline |
Address | 50 Broadway, London, United Kingdom, SW1H 0DB |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 908 |
